Clinical Transplantation

Cover image for Vol. 31 Issue 6

Edited By: Ron Shapiro, MD

Impact Factor: 1.844

ISI Journal Citation Reports © Ranking: 2015: 16/25 (Transplantation); 78/200 (Surgery)

Online ISSN: 1399-0012

Just Published Articles

  1. Impact of terlipressin infusion during and after live donor liver transplantation on incidence of acute kidney injury and neutrophil gelatinase-associated lipocalin serum levels: A randomized controlled trial

    Mohamed A. Kandil, Khalid M. Abouelenain, Ayman Alsebaey, Hanaa S. Rashed, Mohamed H. Afifi, Mohamed A. Mahmoud and Khaled A. Yassen

    Version of Record online: 25 JUN 2017 | DOI: 10.1111/ctr.13019

  2. No effect of HLA-C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T-cell depletion in patients with hematological malignancies

    Isabelle Magalhaes, Michael Uhlin, Marie Schaffer, Mikael Sundin, Dan Hauzenberger, Mats Remberger and Jonas Mattsson

    Version of Record online: 25 JUN 2017 | DOI: 10.1111/ctr.13012

  3. The impact of calcineurin inhibitors on neutrophil gelatinase-associated lipocalin and fibroblast growth factor 23 in long-term kidney transplant patients

    Inger Hjørdis Bleskestad, Inga Strand Thorsen, Grete Jonsson, Øyvind Skadberg and Lasse Gunnar Gøransson

    Version of Record online: 23 JUN 2017 | DOI: 10.1111/ctr.13015

  4. Dual kidney transplant techniques: A systematic review

    Annelise Cocco, Sara Shahrestani, Nicholas Cocco, Ahmer Hameed, Lawrence Yuen, Brendan Ryan, Wayne Hawthorne, Vincent Lam and Henry Pleass

    Version of Record online: 23 JUN 2017 | DOI: 10.1111/ctr.13016

  5. Kidney transplantation from donors with rhabdomyolysis and acute renal failure

    Chuan-bao Chen, Yi-tao Zheng, Jian Zhou, Ming Han, Xiao-ping Wang, Xiao-peng Yuan, Chang-xi Wang and Xiao-shun He

    Version of Record online: 22 JUN 2017 | DOI: 10.1111/ctr.13021

More

CTR | Transplant Peer Review Network

1


Clinical Transplantation participates in the Wiley Transplant Peer Review Network

Download today | Clinical Transplantation app

CTR app


Available in the App StoreSM: iPad®, iPhone®, and iPod touch®
Subscribers: follow the registration wizard for full access.

In Memoriam

Dr_Starzl

The Legacy of Thomas E. Starzl, MD, PhD 3/11/1926 – 3/4/2017

One of the great pioneers (some would argue the greatest pioneer) in the history of transplantation passed away in his sleep in the early morning of March 4, 2017, one week shy of his 91st birthday. His accomplishments would have been enough for any 6 incredibly productive careers—over 2200 papers, 1300 lectures, several books, and critical roles in the development of clinical immunosuppression, kidney, liver, pancreas, and small bowel transplantation, and the mentorship of generations of leaders in the field of transplantation. A member of every important surgical and medical society, including the Institute of Medicine and the American Philosophical Society, he received virtually every award imaginable, including the National Medal of Science, the Lasker award, and the Medawar Prize (of the Transplantation Society), with the exception of the Nobel Prize (for which he had been nominated). His contributions to the development of clinical immunosuppression began with the demonstration that azathioprine and prednisone represented a successful approach in kidney transplantation, at a time when any sort of routine engraftment had not yet been achieved. He continued with the demonstration of the efficacy of cyclosporine in liver, kidney, heart, lung, and pancreas transplantation, and the improved efficacy of tacrolimus as an immunosuppressive agent, allowing routine withdrawal or even avoidance of corticosteroids. His perseverance led to the first successful liver transplants, at a time when few shared his conviction that it was achievable. His demonstration of micro chimerism in long surviving kidney recipients and his attempts at tolerogenic immunosuppression and xenotransplantation reflected the diversity of his scientific interests.

There were, however, two fundamental aspects of his world view that directed all of his endeavors, and that remain lessons and a legacy for all of us. First, he was fundamentally a clinician, and everything that he did was focused on improving the welfare of his patients. He celebrated their successes, and mourned their deaths. Second, and perhaps most important, he was never satisfied. Everything could be improved—immunosuppression, technical approaches, minimization of side effects—and he was never complacent about what had been achieved. This unwillingness to accept what had been achieved as the last word was pervasive throughout his career, and drove him to continue to improve everything he touched. His lack of complacence remains an ongoing challenge for those of us who have continued in the field.

Dr. Starzl was an important mentor to just about everyone in the field of transplantation, either directly, or one or two generations removed. His record of accomplishment is humbling to the rest of us, and he is a role model for his dedication and perseverance in the face of criticism and active hostility (new ideas are never easily accepted, and he generated new ideas throughout his career). He will be missed by all of us who knew him and all of the patients whose lives he saved and enriched.

New Content Alerts

Never miss an issue of Clinical Transplantation!

E Alerts

Free, customizable e-mail content alerts notify you of articles or issues as they publish, in the frequency and format you prefer. Sign up today and never miss an issue.

content alertAlerts: Log in (top right), then click this icon in the Journal Tools menu (left).

Read A Sample Issue Today!

Sample Issues Available

Did you know that you can download all the articles from the January 2016 issue for free? Check it out today!

SEARCH

SEARCH BY CITATION